読み込み中
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
前日終値
$2.13
+$0.01 · +0.47%
日中の時刻はETです。市場データは遅延する場合があります。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日中レンジ
現在 $2.13
52週レンジ
現在 $2.13
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
70
割安
センチメント
61
強気
リスク
85
極めて高いリスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日中レンジ
現在 $2.13
52週レンジ
現在 $2.13
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 297.64万 USD | 250.03万 USD | 254万 USD | 170.69万 USD | 116.07万 USD |
| 粗利益 | 297.64万 USD | 250.03万 USD | 254万 USD | 170.69万 USD | 116.07万 USD |
| 研究開発 | 306.55万 USD | 328.83万 USD | 349.48万 USD | 477.08万 USD | 316.35万 USD |
| 販売・一般管理 | 274.55万 USD | 341.64万 USD | 356.09万 USD | 365.4万 USD | 374.4万 USD |
| 営業費用 | 581.1万 USD | 670.47万 USD | 705.57万 USD | 842.48万 USD | 690.75万 USD |
| 受取利息 | 14.8万 USD | 24.99万 USD | 35.58万 USD | 16.72万 USD | 10.05万 USD |
| 減価償却費と償却費 | — | 15.33万 USD | — | 2.7万 USD | 3.55万 USD |
| 営業利益 | −283.46万 USD | −420.44万 USD | −451.57万 USD | −671.79万 USD | −574.68万 USD |
| 純利益 | −268.09万 USD | −396.03万 USD | −413.46万 USD | −655.24万 USD | −564.52万 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年5月15日 | 1:10 | — | — |
株式分割 | 2019年6月25日 | 1:12 | — | — |
株式分割 | 2016年6月6日 | 1:33 | — | — |
発効済み 2023年5月15日
1:10
発効済み 2019年6月25日
1:12
発効済み 2016年6月6日
1:33
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
